Benlysta
GSK’s Benlysta becomes first FDA-approved IV therapy for paediatric lupus
April 30, 2019Manufacturing and Production, Sales and Marketing Benlysta, FDA, GSK, Lupus, US, pharma
GSK has scored approval in the US with Benlysta (belimumab) for the treatment of systemic lupus erythematosus (SLE) in paediatric …
Interview: GSK’s subcutaneous formulation for Benlysta may help cut down hospital visits
June 22, 2016Research and Development Benlysta, EULAR, Interview, Lupus, NICE, autoimmune diseases, drug trial
UK drugmaker GlaxoSmithKine (LSE: GSK) reported positive results for Benlysta following a late-stage study at the annual European Congress of …
GSK ready for lupus drug push
November 12, 2015Manufacturing and Production, Research and Development, Sales and Marketing Benlysta, GSK, Lupus, SLE, belimumab, systemic lupus erythematosus
Having presented positive late-stage results for a new formulation of its inflammatory drug Benlysta, GSK says it will file supplementary …
Benlysta once again rejected by NICE
July 25, 2013Sales and Marketing Benlysta, GSK, NHS, NICE
NICE has opened a second public consultation for GSK’s lupus drug Benlysta after the Institute has again rejected the medicine …
Glaxo seals $3 billion acquisition of HGS
July 17, 2012Business Services, Research and Development, Sales and Marketing Benlysta, GSK, Human Genome Sciences, R&D
GlaxoSmithKline has finally sealed the acquisition of Human Genome Sciences, the company with which it co-markets lupus treatment Benlysta. The …
HGS shareholder challenges ‘poison pill’
May 31, 2012Sales and Marketing Benlysta, GSK, HGS, hostile bid
The saga of GlaxoSmithKline’s attempt to take over Human Genome Sciences (HGS) has taken another turn with legal action by …
NICE no to GSK’s lupus drug Benlysta
April 27, 2012Sales and Marketing Andrew Dillon, Benlysta, GSK, Lupus, NICE
NICE is still not recommending GlaxoSmithKline’s lupus drug Benlysta, as it believes the treatment is too costly. In its final …
GSK’s bid for Human Genome Sciences rejected
April 19, 2012Sales and Marketing Benlysta, GSK, Human Genome Sciences, mergers and acquisitions
GlaxoSmithKline has launched a takeover bid for Human Genome Sciences for around $2.5 billion, but has been rejected by the …
Key product launches of 2011
December 19, 2011Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2011, Actos, Benlysta, Brilique, Eliquis, Eylea, Incivek, Jevtana, Multaq, Victrelis, Xalkori, Yervoy, Zytiga, avastin, gilenya, key products
Avastin 2011 saw a handful of high profile drugs suffer because of new safety and efficacy concerns. Chief among these …
Rumours abound on GSK-HGS takeover bid
October 20, 2011Research and Development, Sales and Marketing Benlysta, GSK, HGS
Rumours are gathering pace that GlaxoSmithKline may launch a takeover bid for struggling US firm Human Genome Sciences. British tabloid …
European recommendation for GSK’s lupus drug Benlysta
May 23, 2011Sales and Marketing Benlysta, CHMP, GlaxoSmithKline, Lupus
GlaxoSmithKline’s first-in-class lupus drug Benlysta has been given a major boost by regulators in the European Union. The European Medicines …
Lonza expands UK facility, bio business reports growth
April 13, 2011Manufacturing and Production, Research and Development, Sales and Marketing Benlysta, Lonza, Slough, manufacturing
Swiss contract manufacturer and fine chemicals company Lonza has said it plans to expand its biopharmaceutical production unit in Slough, …
US approval for GSK’s lupus treatment Benlysta
March 10, 2011Sales and Marketing Benlysta, GSK, GlaxoSmithKline, Human Genome Sciences, Lupus, belimumab, systemic lupus erythematosus
GlaxoSmithKline’s lupus treatment Benylsta has won an historic approval in the US, but will have to prove its safety record …
Key drug launches for 2011
January 20, 2011Sales and Marketing Benlysta, Cladribine, Movectro, Pradaxa, Xarelto, axitinib, boceprevir, crizotinib, telaprevir
This year is expected to see new treatments for hepatitis C, multiple sclerosis and lupus among those that could reach …
UCB lupus candidate shows disease benefits
November 11, 2010Benlysta, Lupus, UCB, epratuzumab, monoclonal antibody, systemic lupus erythematosus
A new monoclonal antibody targeting the autoimmune disease lupus is continuing to show a positive effect on sufferers, its manufacturer …
